Conectar
Chronic prurigo is frequently complicated by chronic wounds and secondary bacterial infections, representing a major therapeutic challenge. A betulin-containing gel, approved for wound treatment in epidermolysis bullosa, has demonstrated wound-healing and antimicrobial properties beyond its licensed indication. To describe the clinical course of a chronic, recurrently superinfected wound in chronic prurigo treated with a betulin-containing topical gel. A 53-year-old male with chronic prurigo under systemic therapy with the Interleukin-4 and -13 antibody Dupilumab, presented with a persistent ulcerative lesion at the mandibular angle, repeatedly colonized by pathogenic bacteria despite prior systemic and topical antimicrobial therapy. Betulin-containing gel was applied twice daily under occlusion for 3 weeks. Clinical outcomes and microbiological findings were assessed. After 3 weeks of treatment, marked clinical improvement was observed, including reduced erythema and crusting, resolution of pain and itch, and complete epithelial stabilization. Follow-up wound swabs were negative for pathogenic bacteria. This case suggests that betulin-containing gel may represent a useful adjunctive treatment option for complex, superinfected chronic wounds in chronic prurigo. Further controlled studies are required to clarify its role in multimodal wound management.
FreshRSS 